Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Oncology·MeSH: Ovarian Neoplasms

Prevalence

24.0 / 100K

Incidence

10.6 / 100K/yr

5 drugs in development·1 company·1 clinical trial

Drug Pipeline by Phase

Compare drugs

Administration of ceralasertib vs Administration of ceralasertib in combination with AZD5305Administration of ceralasertib vs Administration of ceralasertib monotherapyAdministration of ceralasertib vs Administration of ceralasertib and olaparib

Frequently asked questions

How many drugs are in development for Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer?

BioSniper tracks 5 drugs in development for Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer across 1 company.

How many clinical trials target Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer?

There are 1 clinical trial targeting Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer tracked by BioSniper.

What is the prevalence of Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer?

The estimated prevalence of Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer is approximately 24.0 per 100,000 population.

Deep-dive into Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer — Drugs in Development & Clinical Trials | BioSniper